WO2015066432A8 - Methods of treating post-myeloproliferative neoplasms (mpns) and post-mpn acute myeloid leukemia - Google Patents

Methods of treating post-myeloproliferative neoplasms (mpns) and post-mpn acute myeloid leukemia Download PDF

Info

Publication number
WO2015066432A8
WO2015066432A8 PCT/US2014/063353 US2014063353W WO2015066432A8 WO 2015066432 A8 WO2015066432 A8 WO 2015066432A8 US 2014063353 W US2014063353 W US 2014063353W WO 2015066432 A8 WO2015066432 A8 WO 2015066432A8
Authority
WO
WIPO (PCT)
Prior art keywords
post
methods
myeloid leukemia
mpns
mpn
Prior art date
Application number
PCT/US2014/063353
Other languages
French (fr)
Other versions
WO2015066432A1 (en
Inventor
Matthew J. HAWRYLUK
Vincent A. MILLER
Philip James STEPHENS
Kai Wang
Omar Abdel-Wahab
Ross LEVINE
Raajit RAMPAL
Marcel Van Den Brink
Original Assignee
Foundation Medicine, Inc.
Memorial Sloan-Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foundation Medicine, Inc., Memorial Sloan-Kettering Cancer Center filed Critical Foundation Medicine, Inc.
Publication of WO2015066432A1 publication Critical patent/WO2015066432A1/en
Publication of WO2015066432A8 publication Critical patent/WO2015066432A8/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

Methods and compositions for treating post-myeloproliferative neoplasm acute myeloid leukemia are disclosed.
PCT/US2014/063353 2013-11-01 2014-10-31 Method of treating post-myeloproliferative neoplasms (mpns) and post-mpn acute myeloid leukemia WO2015066432A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361898807P 2013-11-01 2013-11-01
US61/898,807 2013-11-01

Publications (2)

Publication Number Publication Date
WO2015066432A1 WO2015066432A1 (en) 2015-05-07
WO2015066432A8 true WO2015066432A8 (en) 2015-10-29

Family

ID=53005169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/063353 WO2015066432A1 (en) 2013-11-01 2014-10-31 Method of treating post-myeloproliferative neoplasms (mpns) and post-mpn acute myeloid leukemia

Country Status (1)

Country Link
WO (1) WO2015066432A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3307254B1 (en) * 2015-06-11 2020-08-05 The Medical College of Wisconsin, Inc. Mito-honokiol compounds and methods of synthesis and use thereof
US11897910B2 (en) 2015-06-11 2024-02-13 The Medical College Of Wisconsin, Inc. Mito-honokiol compounds and methods of synthesis and use thereof
WO2020033585A1 (en) * 2018-08-07 2020-02-13 The Broad Institute, Inc. Methods for combinatorial screening and use of therapeutic targets thereof
CN115054695A (en) * 2022-07-19 2022-09-16 中南大学湘雅二医院 Application of MEK/ERK signal pathway inhibitor in preparation of medicine for treating myeloproliferative tumors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8227202B2 (en) * 2008-07-10 2012-07-24 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment

Also Published As

Publication number Publication date
WO2015066432A1 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
WO2015066452A3 (en) Methods of treating pediatric cancers
MX2016003843A (en) Irak inhibitors and uses thereof.
IL243752A0 (en) Multispecific antibodies, compositions comprising same and uses thereof
WO2014011911A3 (en) Irak inhibitors and uses thereof
HK1211866A1 (en) Antioxidant compositions and methods of using the same
HK1213838A1 (en) Methods and compositions for coating substrates
EP3269109A4 (en) Methods and arrangements for multipath traffic aggregation
MX2015008999A (en) Mk2 inhibitors and uses thereof.
SG11201708144TA (en) An intumescent coating composition
EP3007695A4 (en) Compositions and methods for treating anemia
EP3277270A4 (en) Compositions and methods for treating anemia
EA201591615A1 (en) SUBSTITUTED XANTHESES AND METHODS OF THEIR APPLICATION
EP3145542A4 (en) Methods for characterizing and treating acute myeloid leukemia
HK1215790A1 (en) Methods of treating myeloid leukemia
MX2016009590A (en) Apilimod compositions and methods for using same.
HK1255453A1 (en) Methods and compositions for treating leukemia
MY175418A (en) Compositions comprising anti-cd38 antibodies and carfilzomib
HK1245302A1 (en) Carrier molecule compositions and related methods
HK1210986A1 (en) Methods and compositions for coating substrates
MX2015009818A (en) Pparî³ agonists for treatment of multiple sclerosis.
EP3052102A4 (en) Compositions and methods for treating cancers
EP3065550A4 (en) Methods and compositions for treating sepsis
EP3065829A4 (en) Compositions and methods for treating melanoma
EP3429613A4 (en) Compositions and methods for treating cancers
WO2015066432A8 (en) Methods of treating post-myeloproliferative neoplasms (mpns) and post-mpn acute myeloid leukemia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14858103

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14858103

Country of ref document: EP

Kind code of ref document: A1